July 22, SHANGHAI—Effepharm proudly welcomes Dr. Richard Kaszynski, a distinguished figure in medical research and global healthcare, to EffePharm's esteemed Advisory Board. Dr. Kaszynski brings a wealth of knowledge and expertise to EffePharm, with a stellar background as a former Research Fellow at Harvard Medical School and extensive experience in emergency medicine and healthcare strategies in various parts of the world. He is also a founder of the Stanford SOLUTIONS program, promoting equitable healthcare innovations globally. "NAD+ biology research holds the key to understanding age-related declines and diseases," said Dr. Richard H. Kaszynski, MD. "Our collaboration with EffePharm aims to pioneer advancements in this crucial field, driving transformative results in wellness and longevity. Current studies on NMNH demonstrate great potential, positioning it as the next-generation NAD+ booster. I am incredibly excited about EffePharm’s ongoing phase I clinical study on UthPeak™ NMNH, which promises groundbreaking advancements in preventive medicine and age-related disease intervention." At EffePharm, the company is committed to providing scientifically backed solutions for enhanced wellness and anti-aging benefits. EffePharm is proud of the groundbreaking clinical trial on UTHEVER®, the world's first clinically proven NMN brand. The journey continues with UthPeak™ NMNH. UthPeak™ NMNH has gone through rigorous toxicology testing…

-- Exploring the Anti-Aging Mechanisms and Health Potential of NMN and NMNH -- July 9, 2024, SHANGHAI – EffePharm is pleased to announce the signing of a significant three-year collaboration agreement with the team of Dr. Zheng Songguo from Shanghai Jiao Tong University. This collaboration is part of EffePharm’s latest effort to explore, develop, and scale new wellness solutions, working directly with research institutes to delve deeply into the anti-aging mechanisms and health potential of NMN and NMNH (Reduced NMN). EffePharm's flagship NAD+ supplements, the "Uth Series"—including UTHEVER® NMN and UthPeak™ NMNH—have been dedicated to unveiling the “secrets of youth” through clinical-backed evidence since their inception. Through this collaboration with Dr. Zheng's team, EffePharm aims further to investigate the anti-aging mechanisms of NMN and NMNH, particularly focusing on molecular mechanisms involved in mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and telomere attrition. Additionally, the collaboration seeks to explore more health potentials and market applications of these “star” ingredients. Dr. Zheng Songguo is the Chair Professor at Shanghai Jiao Tong University and serves as the Director of the Institute of Cell and Gene Therapy. He is also the Chief Scientist for a key research and development project by China's Ministry of…

SHANGHAI, China—EffePharm, the trailblazing biotech company, takes a moment to appreciate the incredible journey experienced at SupplySide West 2023, held at Mandalay Bay in Las Vegas. The event marked the introduction of UthPeak™, a captivating newcomer to the "Uth" series, EffePharm's esteemed flagship NAD+ booster line. The atmosphere at the EffePharm booth was nothing short of lively, with visitors and clients expressing genuine curiosity and enthusiasm for EffePharm's latest anti-aging innovations. UthPeak™, a patent-pending crystalline NMNH, emerged as a focal point, promising to be the next star in the realm of NAD+ boosters.  EffePharm is conducting research and development around the twelve hallmarks of aging, including UTHEVER® NMN, UTHEVER® Lipo liposomal NMN, ApiAge™ apigenin, and SuperMide™ Spermidine. The engaging discussions and shared excitement underscored EffePharm's commitment to creating wellness solutions grounded in clinical evidence.   Effe-IDS (Ingredient Delivery System), introduced during the event, offered a glimpse into the company's dedication to advancing active ingredient delivery. The system's use of innovative technologies such as LipoAvail™, EncapCirc™, and CelleSperse™ hinted at a future where bioavailability and functionality are seamlessly optimized.   SupplySide West 2023 served as a platform for EffePharm to connect with industry professionals and enthusiasts, fostering an atmosphere of collaboration…

EffePharm to Launch UthPeak™ at SupplySide West 2023 New member of the “Uth series” – EffePharm’s flagship NAD+ booster line SHANGHAI, China—Industry leading biotech company EffePharm will unveil its Next-Gen NAD+ Booster, UthPeak™, at booth #4965 during the SupplySide West 2023 from October 25 to 26 at Mandalay Bay in Las Vegas.   At booth #4965, EffePharm will showcase the “Uth series,” featuring groundbreaking anti-aging ingredients, including UthPeak™ NMNH, UTHEVER® NMN, and UTHEVER® Lipo liposomal NMN. Additionally, the frontier anti-aging ingredients range, which includes ApiAge™ apigenin and SuperMide™ Spermidine. Furthermore, the company will unveil the Effe-IDS, the advanced active ingredient delivery system utilizing LipoAvail™ liposomal technology, EncapCirc™ microencapsulation technology, and CelleSperse™ micelles technology.   SupplySide West 2023 is renowned for bringing together the brightest minds and top companies in the nutraceutical industry. EffePharm’s new initiative at SupplySide West 2023 aims to assist nutrition and health companies in developing user-friendly products with clinically-based concepts, and health solutions powered by advanced nutrient delivery methods to address the unmet health needs of individuals across all age groups.   UthPeak™: The Next-Gen Super NAD+ Enhancer UthPeak™ is a patent-pending crystalline NMNH, a reduced form of nicotinamide mononucleotide (NMN). “We firmly believe that UthPeak™ NMNH has the potential to become the…

Radiotherapy is one of the main treatment options for many different types of cancers as it has a high success rate in destroying cancerous cells. However, there is no existing way to prevent the inevitable harm caused by the ionizing radiations on neighbouring healthy cells and tissues.​ 60-80% of patients undergoing radiotherapy for abdominal or pelvic cancers displayed radiation-induced intestinal damage among other complications.1​ Nicotinamide mononucleotide (NMN), the precursor of NAD+ (Nicotinamide Adenine Dinucleotide), has been shown to bring many benefits to its users and NMN supplementation is shown to relieve the aforementioned damage and complications caused by radiotherapy.   Radiation induced intestinal damage and complications​ The intestinal tract is notable for the fast renewal and proliferation of its cells, which results in the organ’s increased receptivity to stimulation from the environment. Patients who undergo radiotherapy for the treatment of abdominal and pelvic tumours are at an increased risk of developing early intestinal injury manifestations such as abdominal distention, abdominal pain, nausea, loss of appetite, and acute diarrhoea.2​ These symptoms have significant negative impact on the patient's quality of life. Additionally, older adults usually have an altered intestinal structure, decreased regenerative and proliferative ability, and other aspects, all of which could…

–Work jointly to protect access to NMN dietary supplements—   SHANGHAI, China, May 02, 2023 –  As part of the growth and outreach to handle the large-scale demand of finished NMN product manufacturers in the U.S., including the lead on NMN legalization, EffePharm announced today that it had joined the Natural Products Association (NPA), USA.     The NPA is the oldest and largest association dedicated to the dietary supplements industry. As the industry watchdog on regulatory and legislative issues, NPA is recognized for its strong lobbying presence in Washington, D.C.   In November 2022, the Food and Drug Administration (FDA) issued a notice declaring that beta-nicotinamide mononucleotide (NMN) could not be marketed as a dietary supplement in the U.S. In response, in March 2023, the Natural Products Association (NPA), along with the Alliance for Natural Health (ANH), filed a citizen petition with the FDA. The petition requests the FDA withdraw its decision to exclude NMN from being classified as a supplement and to use “enforcement discretion in connection with the marketing and selling of NMN in or as a dietary supplement.”   The EffePharm membership reflects the supplements industry’s willingness to reverse FDA’s decision on NMN. The new partnership will facilitate…

On 5th May 2022, Frontier in Aging, an authoritative international journal on aging mechanisms, published one NMN clinical trial report with new insights and more experience being brought into the field of longevity. This human clinical trial conducted by Effepharm Ltd, was started in 2020. Previously Effepharm as one leading NMN manufacturer, finished the animal testings as well, proving that NMN has no acute toxicity. Frontiers in Aging, one of the largest and highest-cited publishers in the world, led and peer-reviewed by editorial boards of over 100,000 top researchers, agreed to publish UTHEVER® NMN’s human clinical trials, which was reviewed by scientists, including professors at Harvard Medical School. This is the first time that Effepharm released detailed trial data to the public. Figure 1 https://www.frontiersin.org/articles/10.3389/fragi.2022.851698/full The main purpose of this trial is to investigate the safety of the first branded NMN ingredient– UTHEVER®. Meanwhile, this study also included some efficacy tests. Here are the conclusions of UTHEVER®NMN human trial: The study was carried out on 66 healthy subjects between the ages of 40 and 65 years, instructed to take two capsules (each containing 150 mg. of NMN or starch powder) once a day after breakfast for 60 days. Safety: Mild dyslipidemia…

On July 9th, Dr. Liu from Effepharm delivered a speech entitled “UTHEVER®, NMN’s Modified Advanced Technology by Effepharm” at HFIC(Healthy China 2021 Nutrition and Health Food Conference), telling the advanced R&D concept of Effepharm’s NMN – QbD (Quality by Design). As the first Chinese company to conduct clinical research on NMN, Effepharm has been making unremitting efforts in the NMN project and constantly demonstrates the safety and effectiveness of NMN with scientific technology. Since June 2017, the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) has required the use of the QbD concept. In 2018, CFDA claimed that biomedical products that do not conform to the QBD development concept will not be approved by CFDA for marketing. We can see that only drug products under the guidance of QbD can achieve quality control, Effepharm is to use this concept to ensure the quality control of product batches. Under this R&D concept, Effepharm has developed a strict quality management system, considering the product design and development, production process route selection, and determination from the beginning of the research and development stage. As the first and only one brand of NMN raw material, UTHEVER ®…

The administration of Nicotinamide mononucleotide(NMN) which is a key precursory metabolite of NAD+ has been reported to have remarkable therapeutic effects on age-related diseases. However systemic evaluation pertaining to the subacute toxicity of NMN remains to be determined.   Recently, the Shanghai Institute of Organic Chemistry conducted a study about the subacute toxicity of NMN in mice and beagle dogs, both of which were gavaged with a saturated concentration of NMN solution at the maximum intragastric dose once or twice per day for 7 or 14 days (Figure 1). Figure 1 In mice, NMN administrated once per day for 7 days is well tolerated with minimal deleterious effects. Upon higher dosage, they observe a slightly increased level of alanine aminotransferase, while other biomarkers remain unchanged (Figure 2). Figure 2 Consistently, administration of NMN in beagle dogs only results in mild increases in creatinine and uric acid (Figure 3). Figure 3 Interestingly, in mice that received higher NMN dosage, measurements of blood lipids, including total cholesterol, triglyceride, and low-density lipoprotein cholesterol, were significantly decreased which indicated that the lipid metabolic process being prominently highlighted (Figure 4). Figure 4   Despite the administration of NMN was conducted in the short-term, it is…

Effepharm’s R&D Director got an outstanding achievement award for scientific research Dr. Jianjun Yu, Effepharm’s R&D Director,  got an outstanding achievement award for scientific research of the ministry of education in October 2019. The winning project was “Rare earth micellar catalysis technology of green fine organic synthesis”.   Through many years’ efforts, the group developed a series of rare earth micellar catalysts and catalysis technology. Dr. Jianjun Yu applies it to the green synthesis process of conventional medicine, food supplements, and high-end health care molecules. These catalysts and the catalysis technology can effectively reduce or avoid the use of noxious reagents or solvents to ensure the safety and stability of chemically synthesized products. With this catalysis technology, the purity of UTHEVER’s patented NMN powder can be up to 99.9%, guaranteeing no hazardous chemical impurities are left. Catalysts including enzymes are important in chemical and biological reactions. Usually, catalysts can speed the reactions with lower energy and temperature. With Dr. Yu’s rich experience, Effepharm is developing a more and more efficient and eco-friendly process. Incorporating these high techs into our manufacturing, Effepharm is supplying dietary ingredients including NMN-UTHEVER, to the world at very competitive prices.

From 16Dec to 18Dec 2020, Effepharm will attend CPhi 2020 in Shanghai, China. As an exhibitor, our booth will be E5A08 At the expo, Effepharm will introduce its next-generation NMN - UTHEVER® to our customers and the public. Looking forward to meeting you at CPhi 2020.

Undoubtedly, the whole world is undergoing great shock under the COVID-19 circumstance. According to some statistics, the number of deaths caused by coVID-19 in the US is equivalent to crushing two civilian airplanes every day. And scientists have devoted themselves to search for the most effective curing method, including NMN cocktail therapy and mRNA a vaccine. Pfizer /BioTech recently announced that its vaccine was 90% effective. Moderna also announced its first interim analysis of phase III clinical trials of its covid-19 vaccine candidate, which showed an efficacy rate of 94.5%. Taking advantage of this opportunity, we would like to review once again the treatment of a 55-year-old severe coVID-19 case with NMN from the United States in April this year and the difference between NMN cocktail therapy and mRNA vaccine. Currently, most developed vaccines are mRNA vaccines, which target the coronavirus precisely. In theory, scientists make a synthetic version of the mRNA that viruses use to build their infectious proteins. Cells would read the delivered mRNA as instructions for building the virus’s protein to make some of the virus’s molecules themselves. These proteins are independent, so they do not assemble into viruses. The immune system then detects these viral proteins and begins…